What Researchers Did
Researchers conducted a retrospective analysis of 54 patients (30 treated with hyperbaric oxygen therapy and 24 without) to examine its effectiveness in treating major truncal necrotizing infections between 1980 and 1992.
What They Found
The study found no significant difference in mortality rates, with 30% (9/30) in the hyperbaric oxygen group and 42% (10/24) in the non-hyperbaric oxygen group. There were also no differences in hospital stay, ICU stay, or antibiotic therapy duration, though the hyperbaric oxygen group underwent more operations.
What This Means for Canadian Patients
While this study did not statistically prove that hyperbaric oxygen therapy reduces mortality or the number of débridements for major truncal necrotizing infections, a trend towards increased survival was observed. Canadian patients with these serious infections should discuss all treatment options, including hyperbaric oxygen therapy, with their medical team, recognizing the need for further research.
Canadian Relevance
This multicenter retrospective study was conducted by Canadian researchers, indicating its direct relevance to healthcare practices and patient outcomes within Canada.
Study Limitations
Limitations include the retrospective design, a selection bias towards younger patients with more frequent clostridial infections in the hyperbaric oxygen group, and a lack of statistical power to show a definitive benefit.